Colonoscopy Prep Costs & ACA: Still Paying?
The Affordable Care Act (ACA) mandates no-cost coverage for colonoscopy screenings, yet many patients are still facing unexpected out-of-pocket expenses for colonoscopy prep. This revealing analysis, published in Gastroenterology, shows over half of commercially insured and a staggering 83% of Medicare beneficiaries are still paying for bowel preparation. Primary_keyword “colonoscopy prep costs” and secondary_keyword “ACA compliance” are central to this critical issue. Low-volume preparations are often most expensive, with potential impacts on screening rates and equity. For in-depth coverage and updates, check out News Directory 3. Discover what’s next for patient access and improved healthcare outcomes.
ACA Mandate Falls Short: Colonoscopy Prep Costs Still Burden Patients
Despite the Affordable Care Act’s (ACA) mandate for no-cost coverage of colorectal cancer screenings, including bowel preparation, a critically important number of patients are still burdened with out-of-pocket expenses. A recent analysis reveals that over half of those with commercial insurance and a staggering 83% of Medicare beneficiaries are paying for colonoscopy prep.
The study, published in Gastroenterology, examined prescription drug claims related to screening colonoscopies. Researchers analyzed data from May 2022 to April 2023,encompassing over 2.5 million bowel preparation prescription claims across commercial,Medicare Part D,and Medicaid plans. The goal was to evaluate out-of-pocket costs for bowel preparations, differentiating between high-volume and low-volume options.
The ACA requires private insurers and Medicare to fully cover all colorectal cancer screening tests recommended by the U.S. Preventive Services Task Force (USPSTF) without cost-sharing. However, inconsistencies arise in defining what constitutes a “screening” test, leading to varied coverage. The USPSTF currently advises that individuals at average risk begin colorectal cancer screening at age 45.
the analysis showed that cost-sharing was prevalent. specifically, 53% of commercial claims, 83% of Medicare Part D claims, and 27% of Medicaid claims involved patient cost-sharing. Low-volume preparations consistently incurred higher out-of-pocket costs compared to high-volume options across all payer types.
For commercial claims, 61% of low-volume preparations had out-of-pocket costs, compared to 35% of high-volume preparations. Medicare saw even larger disparities, with 90% of low-volume and 75% of high-volume claims involving cost-sharing. Medicaid had the smallest gap, with 30% and 27%, respectively.
Median out-of-pocket amounts for non-zero cost-sharing were also higher for low-volume products.Commercial and Medicaid patients paid $60, while Medicare beneficiaries paid $55.99, compared to $10, $1, and $8, respectively, for high-volume options.
Researchers acknowledged limitations, including reliance on claims data that doesn’t capture patient characteristics or over-the-counter preparations. Variations in plan benefits and pharmacy pricing were also not assessed.
Despite thes limitations,the study suggests that unexpected costs disproportionately affect access for underserved groups and discourage the use of more tolerable low-volume prep solutions,hindering progress toward national screening goals and equity in preventive care for colorectal cancer.
“Study findings emphasize the need for consistent enforcement of ACA compliance in health plans and for payer practices to align with evidence-based bowel preparation guidelines to support effective screening,” the researchers wrote.
What’s next
The researchers urge the Centers for Medicare & Medicaid Services (CMS) to reaffirm its 2016 guidance, ensuring that colonoscopy preparations are covered at no cost to patients. Strengthening adherence to this mandate could improve access, increase colorectal cancer screening rates, and promote equitable preventive care.